DDI/OC - Marketed, Unapproved Drugs Webinar - May 2, 2011
The Food and Drug Administration, Center for Drug Evaluation and Research (CDER), is delighted to inform you of a unique opportunity for healthcare professionals, pharmacy students, and medical students in the United States to learn more about the FDA and drug regulation. CDER's Division of Drug Information (DDI) is offering a series of educational webinars, developed by FDA pharmacists and targeted to the needs of all healthcare professionals and students.
These focused webinars support FDA's mission of promoting and protecting public health, through interaction and education to strengthen relationships with future clinicians, researchers, and pharmacists. Fostering this connection will provide a better understanding of FDA's role in public health as a regulatory agency.
On May 2, 2011, CDER's Office of Compliance, Division of New Drugs and Labeling Compliance (DNDLC) presented a webinar titled, "Marketed Unapproved Drugs." Lori Cantin, R.Ph., Pharm.D., presented an overview of the history of drug regulation in the United States, discussed the public health risks associated with marketed, unapproved drugs and FDA's Unapproved Drug Initiative, and identified tools to assist in determining the approval status of prescription drug products.
Download Presentation Slides: Marketed, Unapproved Drugs Webinar (PDF - 1MB)
Web address for viewing: https://collaboration.fda.gov/p12861227/
For More Information: Unapproved Drugs: Drugs Marketed in the United States That Do Not Have Required FDA Approval
If you've never used Connect Pro, get a quick overview:
Test your connection prior to the day of the event:
Adobe, the Adobe logo, Acrobat and Acrobat Connect are either registered trademarks or trademarks of Adobe Systems Incorporated in the United States and/or other countries.